Skip to content
Home » News » Health » New Alzheimer’s drug Kisunla approved by FDA

New Alzheimer’s drug Kisunla approved by FDA

  • / Updated:
  • Staff Report 

The FDA has approved Kisunla, a new drug for early-stage Alzheimer’s Disease, marking a significant breakthrough in treatment.

Kisunla, made by Eli Lilly, is a monthly IV injection designed to slow the decline of the disease and improve the quality of life for patients.

Nearly seven million people in the U.S. live with Alzheimer’s, a number expected to triple by 2060. The new drug offers hope for slowing the disease and maintaining cognitive functions. Kisunla will be available soon, and patients are advised to consult their healthcare providers. More information is available on the Alzheimer’s Association’s website or by calling their 24/7 helpline at 1-800-272-3900.

Categories: HealthNews